NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus
Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder.
The company is approaching pivotal phase III readouts across multiple late stage trials and has launched a new phase II study in autism spectrum disorder.
Definium is also increasing its commercial readiness by expanding leadership and building operational infrastructure as it moves toward a potential launch phase.
For investors watching NasdaqGS:DFTX, this...